Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations

Chemico-Biological Interactions

Volumn 189, Issue 3, 2011, Pages 177-185

  Rivest, Patricia ^a   Renaud, Martin ^a   Thomas Sanderson, J ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Androgenic; GSK 3 ; Indirubins; LNCaP cells; MDA kb2 cells; Catenin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 6 BROMO INDURIBIN 3' OXIME; ALOISINE A; ALSTERPAULLONE; AMINOPURVALANOL; ANDROGEN RECEPTOR; ANDROSTANOLONE; BETA CATENIN; DEXAMETHASONE; FLUTAMIDE; GLYCOGEN SYNTHASE KINASE 3ALPHA; INDIRUBIN; INDIRUBIN 3' OXIME; INDIRUBIN DERIVATIVE; KENPAULLONE; MIFEPRISTONE; OLOMOUCINE; PROSTATE SPECIFIC ANTIGEN; ROSCOVITINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; HUMAN CELL; PHARMACOLOGICAL BLOCKING; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 79551516170     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.11.008     Document Type: Article

References (30)

1. L. Meijer, A.L. Skaltsounis, P. Magiatis, P. Polychronopoulos, M. Knockaert, M. Leost, X.P. Ryan, C.A. Vonica, A. Brivanlou, R. Dajani, C. Crovace, C. Tarricone, A. Musacchio, S.M. Roe, L. Pearl, and P. Greengard GSK-3-selective inhibitors derived from Tyrian purple indirubins Chem. Biol. 10 12 2003 1255 1266
2. P. Friedlander Uber den Farbstoff des antiken Purpurs aus Murex brandaris Ber. Dtsch. Chem. Ges. 42 1909 765 770
3. L. Meijer, M. Flajolet, and P. Greengard Pharmacological inhibitors of glycogen synthase kinase 3 Trends Pharmacol. Sci. 25 9 2004 471 480
4. M. Knockaert, P. Greengard, and L. Meijer Pharmacological inhibitors of cyclin-dependent kinases Trends Pharmacol. Sci. 23 9 2002 417 425
5. V.D. Nair, and C.W. Olanow Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses J. Biol. Chem. 283 22 2008 15469 15478
6. S. Libnow, K. Methling, M. Hein, D. Michalik, M. Harms, K. Wende, A. Flemming, M. Kockerling, H. Reinke, P.J. Bednarski, M. Lalk, and P. Langer Synthesis of indirubin-N′-glycosides and their anti-proliferative activity against human cancer cell lines Bioorg. Med. Chem. 16 10 2008 5570 5583
7. S. Nam, R. Buettner, J. Turkson, D. Kim, J.Q. Cheng, S. Muehlbeyer, F. Hippe, S. Vatter, K.H. Merz, G. Eisenbrand, and R. Jove Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells Proc. Natl. Acad. Sci. U.S.A. 102 17 2005 5998 6003
8. J. Shi, and H.M. Shen Critical role of Bid and Bax in indirubin-3′-monoxime-induced apoptosis in human cancer cells Biochem. Pharmacol. 75 9 2008 1729 1742
9. T. Lahusen, A. De Siervi, C. Kunick, and A.M. Senderowicz Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential Mol. Carcinog. 36 4 2003 183 194
10. C. Schultz, A. Link, M. Leost, D.W. Zaharevitz, R. Gussio, E.A. Sausville, L. Meijer, and C. Kunick Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity J. Med. Chem. 42 15 1999 2909 2919
11. Z. Xiao, Y. Hao, B. Liu, and L. Qian Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China Leuk. Lymphoma 43 9 2002 1763 1768
12. H. Murillo, H. Huang, L.J. Schmidt, D.I. Smith, and D.J. Tindall Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state Endocrinology 142 11 2001 4795 4805
13. G.W. Yardy, and S.F. Brewster Wnt signalling and prostate cancer Prostate Cancer Prostatic Dis. 8 2 2005 119 126
14. D.J. Mulholland, S. Dedhar, H. Wu, and C.C. Nelson PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer Oncogene 25 3 2006 329 337
15. X. Liao, J.B. Thrasher, J. Holzbeierlein, S. Stanley, and B. Li Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer Endocrinology 145 6 2004 2941 2949
16. L. Wang, H.K. Lin, Y.C. Hu, S. Xie, L. Yang, and C. Chang Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells J. Biol. Chem. 279 31 2004 32444 32452
17. G. Wang, J. Wang, and M.D. Sadar Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer Cancer Res. 68 23 2008 9918 9927
18. Y. Li, Z. Wang, D. Kong, R. Li, S.H. Sarkar, and F.H. Sarkar Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells J. Biol. Chem. 283 41 2008 27707 27716
19. X. Yang, M.W. Chen, S. Terry, F. Vacherot, D.L. Bemis, J. Capodice, J. Kitajewski, A. de la Taille, M.C. Benson, Y. Guo, and R. Buttyan Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells Oncogene 25 24 2006 3436 3444
20. D.J. Mulholland, S. Dedhar, G.A. Coetzee, and C.C. Nelson Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr. Rev. 26 7 2005 898 915
21. C.I. Truica, S. Byers, and E.P. Gelmann Beta-catenin affects androgen receptor transcriptional activity and ligand specificity Cancer Res. 60 17 2000 4709 4713
22. V.S. Wilson, K. Bobseine, C.R. Lambright, and L.E. Gray Jr. A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists Toxicol. Sci. 66 1 2002 69 81
23. F. Denizot, and R. Lang Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods 89 1986 271 277
24. M. Leost, C. Schultz, A. Link, Y.Z. Wu, J. Biernat, E.M. Mandelkow, J.A. Bibb, G.L. Snyder, P. Greengard, D.W. Zaharevitz, R. Gussio, A.M. Senderowicz, E.A. Sausville, C. Kunick, and L. Meijer Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25 Eur. J. Biochem. 267 19 2000 5983 5994
25. Q.M. Wang, C.J. Fiol, A.A. DePaoli-Roach, and P.J. Roach Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation J. Biol. Chem. 269 20 1994 14566 14574
26. G.K. Schwartz CDK inhibitors: cell cycle arrest versus apoptosis Cell Cycle 1 2 2002 122 123
27. C.J. Sherr, and J.M. Roberts CDK inhibitors: positive and negative regulators of G1-phase progression Genes Dev. 13 12 1999 1501 1512
28. C. Kunick, K. Lauenroth, M. Leost, L. Meijer, and T. Lemcke 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta Bioorg. Med. Chem. Lett. 14 2 2004 413 416
29. M. Knockaert, M. Blondel, S. Bach, M. Leost, C. Elbi, G.L. Hager, S.R. Nagy, D. Han, M. Denison, M. Ffrench, X.P. Ryan, P. Magiatis, P. Polychronopoulos, P. Greengard, L. Skaltsounis, and L. Meijer Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins Oncogene 23 25 2004 4400 4412
30. L. Schweizer, C.A. Rizzo, T.E. Spires, J.S. Platero, Q. Wu, T.A. Lin, M.M. Gottardis, and R.M. Attar The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens BMC Cell Biol. 9 2008 4